RICHMOND, Calif., May 15, 2017 /PRNewswire/ -- Sangamo
Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome
editing, today announced its support for International MPS
Awareness Day and its commitment to the patients living with MPS I
and MPS II and their families. In partnership with Living in the
Light, an advocacy initiative to shine light on the lives of people
with rare diseases through photography and compelling narratives,
Sangamo highlights stories of hope from the MPS I and MPS II
communities in the Patients & Families section of the Company's
website.
"At Sangamo, our highest priority is to meet the needs of
patients with commitment and compassion. We are proud to support
MPS patients and their families, and honored to be partners in
sharing their stories today in celebration of International MPS
Awareness Day," said Dr. Sandy
Macrae, CEO of Sangamo. "The Sangamo family is committed to
translating our ground-breaking science into new genomic medicines
that will transform the lives of these patients we are trying to
serve. We invite our colleagues, friends and families around the
world to recognize and help raise awareness for these rare genetic
diseases."
Mucopolysaccharidosis Type I (MPS I) and MPS II are rare,
genetic lysosomal storage disorders caused by a missing or
insufficient enzyme that prevents cells from recycling waste,
causing the buildup of complex sugars in the body called
glycosaminoglycans, or GAGs. This leads to damage throughout the
body, affecting vision and hearing, the joints, heart, and other
tissues and organs. Sangamo is developing new genomic therapies for
MPS I and MPS II using the Company's zinc finger nuclease (ZFN)
genome editing technology. These genomic therapies are designed as
a single treatment to provide life-long production of corrective
IDUA and IDS enzymes for MPS I and MPS II respectively, from the
patient's own liver and potentially eliminating the need for
chronic enzyme replacement therapy, or ERT.
About Sangamo
Sangamo Therapeutics, Inc. is focused on
translating ground-breaking science into genomic therapies that
transform patients' lives using the company's industry leading
platform technologies in genome editing, gene therapy, gene
regulation and cell therapy. The Company is advancing Phase 1/2
clinical programs in Hemophilia A and Hemophilia B, and lysosomal
storage disorders MPS I and MPS II. Sangamo has a strategic
collaboration with Pfizer, Inc. for Hemophilia A, with Bioverativ
Inc. for hemoglobinopathies, including beta thalassemia and sickle
cell disease, and with Shire International GmbH to develop
therapeutics for Huntington's disease. In addition, it has
established strategic partnerships with companies in
non-therapeutic applications of its technology, including
Sigma-Aldrich Corporation and Dow AgroSciences. For more
information about Sangamo, visit the Company's website at
www.sangamo.com.
Forward Looking Statements
This press release
contains forward-looking statements regarding Sangamo's current
expectations. These forward looking statements include, without
limitation, statements relating to the potential of Sangamo's
genomic therapies to treat MPS I and MPS II. These statements are
not guarantees of future performance and are subject to certain
risks, uncertainties and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, the dependence on the success of clinical trials of
lead programs, the lengthy and uncertain regulatory approval
process, uncertainties related to the timing of initiation and
completion of clinical trials, whether clinical trial results will
validate and support the safety and efficacy of Sangamo's
therapeutics, and the ability to establish strategic partnerships.
Further, there can be no assurance that the necessary regulatory
approvals will be obtained or that Sangamo and its partners will be
able to develop commercially viable gene-based therapeutics. Actual
results may differ from those projected in forward-looking
statements due to risks and uncertainties that exist in Sangamo's
operations and business environments. These risks and uncertainties
are described more fully in Sangamo's Annual Reports on Form 10-K
and Quarterly Reports on Form 10-Q as filed with the Securities and
Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date, and Sangamo undertakes no
duty to update such information except as required under applicable
law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sangamo-therapeutics-recognizes-international-mps-awareness-day-and-celebrates-the-mps-i-and-mps-ii-communities-with-stories-of-hope-300457755.html
SOURCE Sangamo Therapeutics, Inc.